The global veterinary pharmaceuticals market is experiencing sustained growth as animal healthcare continues to gain importance across both companion animal and livestock sectors. The market, valued at USD 27.41 billion in 2025, is expected to increase from USD 28.98 billion in 2026 to USD 39.37 billion by 2031, expanding at a CAGR of 6.3% during the forecast period. Rising pet ownership, increasing livestock production, growing awareness of animal health, and continuous innovation in veterinary therapeutics are among the key factors driving market expansion worldwide.
Veterinary pharmaceuticals play a critical role in preventing, treating, and managing diseases in animals. These products encompass a broad range of therapeutic categories, including anti-infectives, parasiticides, anti-inflammatory drugs, vaccines, dermatology treatments, and emerging biologics. As animal owners increasingly prioritize the health and well-being of their pets and livestock, demand for advanced veterinary medicines continues to grow across developed and emerging economies.
One of the most influential trends shaping the market is the ongoing rise of pet humanization. Pet owners increasingly view animals as family members and are willing to invest in premium healthcare services, advanced treatments, and preventive care. This shift is driving demand for innovative pharmaceuticals that address chronic conditions, dermatological disorders, pain management, and age-related diseases in companion animals. The growing willingness of pet owners to spend on specialized treatments is creating significant opportunities for pharmaceutical manufacturers.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=243381376
Another major growth driver is the increasing global demand for livestock products, including meat, milk, and poultry. Rising population levels and changing dietary preferences have led to higher livestock production, particularly in emerging economies. This trend has increased the need for effective veterinary pharmaceuticals that help maintain animal health, improve productivity, prevent disease outbreaks, and support food safety standards. Governments and agricultural organizations are also investing in animal health programs to strengthen livestock management practices and minimize economic losses caused by infectious diseases.
Technological advancements are transforming the veterinary pharmaceuticals landscape. The industry is witnessing significant innovation in biologics, monoclonal antibodies, long-acting formulations, and species-specific therapeutics. These next-generation treatments offer improved efficacy, targeted disease management, and enhanced patient compliance. As a result, pharmaceutical companies are increasingly focusing on research and development activities aimed at addressing unmet needs across companion animal and livestock healthcare.
Among product categories, the monoclonal antibodies segment is expected to register the highest CAGR of 7.3% during the forecast period. Monoclonal antibody therapies are gaining attention due to their ability to provide targeted treatment for conditions such as chronic pain, allergic dermatitis, and inflammatory diseases. Their growing adoption reflects a broader shift toward precision medicine approaches within veterinary healthcare.
By route of administration, the oral segment accounted for the largest market share of 48.2% in 2025. Oral medications remain the preferred choice among veterinarians and pet owners due to their convenience, ease of administration, and cost-effectiveness. Tablets, chewable formulations, capsules, and flavored medications continue to dominate treatment protocols across multiple therapeutic areas.
From a formulation perspective, solid formulations held the largest market share of 40.2% in 2025. Solid dosage forms offer advantages such as stability, extended shelf life, precise dosing, and ease of transportation, making them highly popular in veterinary practice. Pharmaceutical manufacturers continue to develop innovative formulations that improve palatability and treatment adherence among animal patients.
The market is also witnessing increasing demand for treatments targeting skin-related disorders. Dermatological diseases are projected to experience the highest growth rate, with a CAGR of 8.6% during the forecast period. The rising prevalence of allergic conditions, skin infections, and inflammatory disorders among companion animals is driving demand for advanced dermatology therapeutics. Innovations in biologics and targeted therapies are expected to further support growth within this segment.
Companion animals represent one of the fastest-growing segments of the veterinary pharmaceuticals market and are projected to register a CAGR of 8.0% through 2031. Increasing pet adoption rates, growing awareness regarding preventive healthcare, and rising expenditure on animal wellness are contributing to strong demand for pharmaceutical products designed specifically for dogs, cats, and other companion animals.
Distribution channels continue to play a vital role in market development. Veterinary hospital pharmacies accounted for the largest share of 65.5% in 2025, reflecting the importance of veterinary institutions in prescribing and dispensing medications. At the same time, the growth of e-commerce platforms and tele-veterinary services is improving access to veterinary drugs, particularly in underserved and remote regions. Digital healthcare models are expected to become increasingly important as consumers seek greater convenience and accessibility.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=243381376
Regionally, North America maintained its leadership position, accounting for 38.4% of the global veterinary pharmaceuticals market in 2025. The region benefits from advanced veterinary healthcare infrastructure, high pet ownership rates, strong awareness of animal welfare, and significant spending on animal health products. Meanwhile, Asia Pacific and Latin America are emerging as high-growth markets due to rising disposable incomes, expanding livestock populations, increasing urbanization, and growing adoption of companion animals.
Leading industry participants such as Zoetis Inc. and Boehringer Ingelheim Animal Health continue to strengthen their market positions through extensive product portfolios, global distribution networks, and ongoing investments in research and innovation. Emerging companies including Phibro Animal Health Corporation and Chanelle Pharma are gaining momentum by focusing on cost-effective therapeutics, niche treatment areas, and geographic expansion strategies.
Looking ahead, advancements in long-acting drug formulations, combination therapies, species-specific medicines, biologics, and digital veterinary healthcare solutions are expected to create substantial growth opportunities. As animal health becomes an increasingly important component of global healthcare and food security initiatives, the veterinary pharmaceuticals market is well-positioned for continued expansion throughout the coming decade.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=243381376